Why Pfizer Stock Was so Healthy in August

Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.

09/08/2026, 4:34 PM • The Motley Fool

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

09/03/2026, 5:30 PM • The Motley Fool

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

09/03/2026, 1:00 PM • GlobeNewswire

Is BioNTech Stock a No-Brainer Buy on the Dip?

BioNTech stock has underperformed significantly, losing 70% over five years as COVID-19 vaccine sales declined. However, the company's mRNA platform is gaining renewed investor interest following Moderna and Merck's successful cancer vaccine trial. BioNTech's diverse pipeline of oncology candidates, including BNT113, BNT116, and pumitamig, could drive future growth, though clinical setbacks remain a risk. The stock appears somewhat attractive but is not a guaranteed buy given its $25.4B valuation and lack of consistent profitability.

09/02/2026, 3:10 PM • The Motley Fool

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

08/26/2026, 9:46 AM • GlobeNewswire

$7+ Billion mRNA Vaccines Market Outlook, 2035: Opportunities, Strategies, Challenges

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

08/26/2026, 9:44 AM • GlobeNewswire

BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock.

BioNTech has appointed Guido Oelkers, former CEO of Swedish rare-disease company Sobi, as its next chief executive, effective February 1, 2027. Oelkers will succeed co-founder Uğur Şahin as BioNTech transitions from a COVID vaccine-focused company to one with a diversified oncology pipeline. The appointment represents a planned transition rather than a strategic shift, with Oelkers' commercial and acquisition experience expected to guide the company through multiple product launches later this decade.

08/13/2026, 9:30 AM • The Motley Fool

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a 10.5% CAGR from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue among HNSCC therapies.

07/21/2026, 1:00 PM • GlobeNewswire

BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt

BioNTech will release second quarter 2026 financial results on August 4, 2026, followed by a conference call. The company will showcase progress across its late-stage oncology pipeline at ASCO 2026, including data on its PD-L1xVEGF-A bispecific pumitamig developed with Bristol Myers Squibb, which demonstrated encouraging efficacy in non-small cell lung cancer patients.

07/21/2026, 6:45 AM • GlobeNewswire

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

BioNTech will announce its second quarter 2026 financial results on August 4, 2026, followed by a conference call. The company will showcase progress across its late-stage oncology pipeline at ASCO 2026, including encouraging efficacy data from the ROSETTA Lung-02 trial for its PD-L1xVEGF-A bispecific pumitamig in non-small cell lung cancer patients, developed in partnership with Bristol Myers Squibb.

07/21/2026, 6:45 AM • GlobeNewswire

Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.

07/13/2026, 1:00 PM • GlobeNewswire

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now

Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (8.2x and 9x forward earnings), they are recommended as potential buys for dividend investors with $1,000 to deploy.

07/07/2026, 6:30 PM • The Motley Fool

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech and Bristol Myers Squibb announced interim Phase 2 data from the ROSETTA Lung-02 trial showing that their investigational bispecific immunomodulator pumitamig combined with chemotherapy demonstrated encouraging anti-tumor activity in first-line non-small cell lung cancer, with confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous subtypes at the lower dose. The drug showed consistent efficacy across PD-L1 expression levels with a manageable safety profile, and is advancing through a comprehensive Phase 3 development program.

05/30/2026, 2:15 PM • GlobeNewswire

Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs

BioNTech and Bristol Myers Squibb announced interim results from the ROSETTA Lung-02 Phase 2/3 study showing that their bispecific PD-L1xVEGF-A immunomodulator candidate Pumitamig demonstrated encouraging anti-tumor activity in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC). The drug showed confirmed objective response rates of 63.6% in non-squamous and 72.7% in squamous NSCLC subtypes at the lower dose, with consistent efficacy across all PD-L1 expression levels. The companies are advancing a comprehensive global Phase 3 development program with multiple ongoing trials.

05/30/2026, 2:15 PM • GlobeNewswire

BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung

BioNTech will present clinical data at the 2026 ASCO Annual Meeting on late-stage oncology pipeline programs, including positive Phase 2 data from ROSETTA Lung-02 for Pumitamig (in combination with chemotherapy for non-small cell lung cancer) and overall survival data for Gotistobart in platinum-resistant ovarian cancer. The company is advancing a diversified portfolio with over 25 Phase 2/3 clinical trials, including 13 ongoing registration-relevant studies.

05/22/2026, 5:00 AM • GlobeNewswire